drugset
drugset / Trial / NCT05766605

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

NCT05766605 ↗

Phase 3 Unknown 90 enrolled Zhujiang Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Timeline

Start
2023-01-01
Primary completion
2026-01-01
Completion
2026-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 50 mg/m2 Other
Subject Doxorubicin Other / unclassified 20 mg/m2 Other
Subject Leucovorin Small molecule 400 mg/m2 Other
Subject Lobaplatin Small molecule 50 mg/m2 Other
Subject Oxaliplatin Small molecule 130 mg/m2 Other
Subject Raltitrexed Small molecule 3 mg Other
Subject fluorouracil Small molecule 2800 mg/m2 Other

Indications

hepatocellular carcinoma